[go: up one dir, main page]

MXPA05003909A - Compuestos de benzopiranona, composiciones de los mismos, y metodos para el tratamiento o prevencion del cancer. - Google Patents

Compuestos de benzopiranona, composiciones de los mismos, y metodos para el tratamiento o prevencion del cancer.

Info

Publication number
MXPA05003909A
MXPA05003909A MXPA05003909A MXPA05003909A MXPA05003909A MX PA05003909 A MXPA05003909 A MX PA05003909A MX PA05003909 A MXPA05003909 A MX PA05003909A MX PA05003909 A MXPA05003909 A MX PA05003909A MX PA05003909 A MXPA05003909 A MX PA05003909A
Authority
MX
Mexico
Prior art keywords
compositions
treating
methods
benzopyranone
preventing cancer
Prior art date
Application number
MXPA05003909A
Other languages
English (en)
Inventor
Wright Jonathan
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of MXPA05003909A publication Critical patent/MXPA05003909A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

La invencion se refiere a compuestos de benzopiranona, a composiciones que comprenden un compuesto de benzopiranona y a metodos para el tratamiento o prevencion del cancer o para la inhibicion del crecimiento de celulas cancerosas o celulas neoplasticas, que comprenden administrar una cantidad efectiva de un compuesto de benzopiranona. Los compuestos de benzopiranona tiene la formula (I), o una sal farmaceuticamente aceptable de los mismos, en donde R1 es halogeno, trifluorometilo o alquilo con C1-6.
MXPA05003909A 2002-10-15 2003-10-15 Compuestos de benzopiranona, composiciones de los mismos, y metodos para el tratamiento o prevencion del cancer. MXPA05003909A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41846902P 2002-10-15 2002-10-15
US10/685,722 US7091235B2 (en) 2002-10-15 2003-10-14 Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer
PCT/US2003/032932 WO2004035002A2 (en) 2002-10-15 2003-10-15 Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer

Publications (1)

Publication Number Publication Date
MXPA05003909A true MXPA05003909A (es) 2005-09-30

Family

ID=32110155

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05003909A MXPA05003909A (es) 2002-10-15 2003-10-15 Compuestos de benzopiranona, composiciones de los mismos, y metodos para el tratamiento o prevencion del cancer.

Country Status (13)

Country Link
US (3) US7091235B2 (es)
EP (1) EP1556374A4 (es)
JP (1) JP2006515275A (es)
KR (1) KR20050072764A (es)
CN (1) CN100457751C (es)
AU (1) AU2003286441A1 (es)
BR (1) BR0315400A (es)
CA (1) CA2502064A1 (es)
IL (1) IL168059A0 (es)
MX (1) MXPA05003909A (es)
NZ (1) NZ539675A (es)
WO (1) WO2004035002A2 (es)
ZA (1) ZA200503026B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091235B2 (en) * 2002-10-15 2006-08-15 Signal Pharmaceuticals, Llc Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer
EP1654225A4 (en) * 2003-08-13 2007-11-28 Amgen Inc HORMONE RECEPTOR ANTAGONISTS CONCENTRATING MELANIN
WO2005019167A2 (en) * 2003-08-13 2005-03-03 Amgen, Inc. Melanin concentrating hormone receptor antagonist
WO2005028472A1 (en) * 2003-09-15 2005-03-31 Signal Pharmaceuticals, Llc Benzopyranone compounds, compositions thereof, and methods of treatment therewith
WO2006078833A2 (en) * 2005-01-21 2006-07-27 Janssen Pharmaceutica N.V. Novel coumarin derivatives as ion channel openers
AU2006262190A1 (en) * 2005-06-24 2007-01-04 Signal Pharmaceuticals, Llc. Benzopyranone compounds for treating cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US633155A (en) 1898-02-23 1899-09-19 William W Ramsay Fence-repairing tool.
US5633155A (en) * 1992-08-19 1997-05-27 Jinro Limited Expression vector for phytolacca antiviral protein and process for preparing transgenic plant transformed therewith
US6444688B1 (en) * 1995-06-07 2002-09-03 Eli Lilly And Company Compounds and compositions with nitrogen-containing non-basic side chains
US6331562B1 (en) * 1998-12-30 2001-12-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6291456B1 (en) * 1998-12-30 2001-09-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
IL144003A0 (en) * 1998-12-30 2002-04-21 Signal Pharm Inc Compounds and methods for modulation of estrogen receptors
KR20020075388A (ko) 1999-12-30 2002-10-04 시그널 파머슈티컬스 인크 에스트로겐 수용체의 조절 화합물 및 조절 방법
US7148252B2 (en) * 2001-10-03 2006-12-12 Signal Pharmaceuticals, Llc Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis
US6620838B1 (en) * 2002-04-19 2003-09-16 Signal Pharmaceuticals, Inc. Benzopyrazone compounds, compositions thereof, and methods of treatment therewith
WO2003089422A1 (en) * 2002-04-19 2003-10-30 Signal Pharmaceuticals, Inc. Benzopyranone compounds, compositions thereof, and methods of treatment therewith
US7091235B2 (en) * 2002-10-15 2006-08-15 Signal Pharmaceuticals, Llc Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer

Also Published As

Publication number Publication date
US7091235B2 (en) 2006-08-15
WO2004035002A2 (en) 2004-04-29
US20080146648A1 (en) 2008-06-19
CN1717405A (zh) 2006-01-04
CN100457751C (zh) 2009-02-04
WO2004035002A3 (en) 2004-08-26
EP1556374A2 (en) 2005-07-27
EP1556374A4 (en) 2007-12-19
KR20050072764A (ko) 2005-07-12
US20060194866A1 (en) 2006-08-31
NZ539675A (en) 2006-10-27
ZA200503026B (en) 2006-11-29
JP2006515275A (ja) 2006-05-25
BR0315400A (pt) 2005-08-16
IL168059A0 (en) 2009-02-11
US7358274B2 (en) 2008-04-15
US7589119B2 (en) 2009-09-15
AU2003286441A1 (en) 2004-05-04
US20040225005A1 (en) 2004-11-11
CA2502064A1 (en) 2004-04-29

Similar Documents

Publication Publication Date Title
PL1678166T3 (pl) Inhibitory kinaz białkowych
WO2001064639A3 (en) Pde iv inhibiting amides, compositions and pharmaceutical use
PL1635835T3 (pl) Pochodne 2-aminopirymidyny jako inhibitory kinazy RAF
IL166298A0 (en) 8-hydroxy quinoline derivatives
MXPA02003977A (es) Inhibidores de adhesion de celula mediada por al°2.
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
GB0112348D0 (en) Compounds
WO2004084812A3 (en) Tamandarin analogs and fragments thereof and methods of making and using
MXPA05009303A (es) Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del vegfr.
DE69907419D1 (en) Antitumorwirkstoffe
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
AP2002002466A0 (en) 3-heterocycliylpropanohydroxamic acid PCP INHIBITORS.
AU2001277659A1 (en) Heteropolycyclic inhibitors
MXPA05003909A (es) Compuestos de benzopiranona, composiciones de los mismos, y metodos para el tratamiento o prevencion del cancer.
WO2004075858A3 (en) Flavone acetic acid analogs and methods of use thereof
GB2426517A (en) Methods and agents for inhibiting dynamin-dependent endocytosis
IL156140A0 (en) Use of substituted 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for treating urinary incontinence
TW200730177A (en) 4 anilino-3-quinolinecarbonitriles for the treatment of cancer
AU2003216965A1 (en) Compounds, particularly of urea derivatives or ester derivatives of haloacetamidobenzoic acid and use thereof for the treatment of parasitic diseases
ATE314059T1 (de) VERWENDUNG VON ßXYLYLOXY ALKYL AMINESß FÜR DIE BEHANDLUNG VON TINNITUS
HK1114854A (en) Benzopyranone compounds for treating cancer

Legal Events

Date Code Title Description
FG Grant or registration